3Egeberg O. On the natural blood coagulation inhibitor system. Investigations of inhibitor factors based on antithrombin deficient blood[J].Thromb Diath Haemorrh, 1965,14(3-4):473-489.
4Bertina R M, Koeleman B P, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C[J]. Nature, 1994,369(6475):64-67.
5Tanaka Y, Ueda K, Ozawa T, et al. Intracellular accumulation of anti-thrombin Morioka C95R a novel mutation causing type Ⅰ anti-thrombin deficiency[J]. J Biol Chem,2002,27,277(52):51058-51067.
6Svensson P J, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis[J]. N Engl J Med, 1994,330(8):517-522.
7Simmonds R E, Ireland H, Kunz G,et al.Identification of 19 protein S gene mutations in patients with phenotypic protein S deficiency and thrombosis[J]. Blood, Dec 1996, 88: 4195-4204.
8Susan A M, Brian C, et al. Combined Tissue Factor Pathway Inhibitor (TFPI) and Thrombomodulin (TM) Deficiency Produces an Augmented Hypercoagulable State with Tissue Specific Fibrin Deposition[J].Blood (ASH Annual Meeting Abstracts),2007,110: 265.
9Genser N, Lechleitner P, Maier J, et al. Rebound increase ofplasminogen activator inhibitor type 1 after cessation ofthrombolytic treatment for acute myocardial infarction is independent of type ofplasminogen activator used[J]. Clinical Chemistry, 1998,44:209-214.
10Sugawara S, Nemoto E, Tada H, et al.Proteolysis of Human Monocyte CD14 by Cysteine Proteinases (Gingipains) from Porphyromonas gingivalis Leading to Lipopolysaccharide Hyporesponsiveness[J]. The Journal of Immunology,2000,165:411-418.
